All In Biotech

Drug Trial Radar · NCT04003155

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

A Phase 3, Randomized, Placebo-controlled, 12-week Double-blind Study, Followed by a Non-Controlled Extension Treatment Period, to Assess the Efficacy and Safety of Fezolinetant in Women Suffering From Moderate to Severe Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 527 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

527

Actual

Start

Jul 11, 2019

Primary completion

Oct 29, 2020

Study completion Aug 11, 2021

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jul 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looks like medicine but did not had any medicine in it.) The study compared fezolinetant and placebo after 4 and 12 weeks of dosing. The study evaluated if fezolinetant reduces the number of hot flashes. And the study evaluated if fezolinetant reduces the severity of the hot flashes. Women in the study received an electronic handheld device at the first study visit. (It was similar to a smart phone.) Each day of the study, study participants used this to record their hot flashes. Their record for the 10 days before the start of study treatment was checked. They remained in the study if their record shown 7 or 8 moderate to severe hot flashes per day (50 or more per week). Next, they were picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It was like flipping a coin. The study participants took study treatment for 52 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors did not knew who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo) during that time. The last 40 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors knew which study treatment that study participant took during that time. Women who took fezolinetant during the first 12 weeks continued to take the same dose. Women who took placebo during the first 12 weeks took fezolinetant. Their dose was either 30 mg or 45 mg fezolinetant. At weeks 2, 4, 8, 12, 14, 16 and then once a month, the study participants visited the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine was collected for laboratory tests. Study participants completed questionnaires that were about how hot flashes affect their daily life. Study participants who still had their uterus had the following 2 tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test is transvaginal ultrasound. This test used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had it done at the last study visit if they are due for their screening mammogram and their own doctor agrees. The last check-up at the hospital or clinic was 3 weeks after the last dose of study treatment.

Conditions

  • Hot Flashes

Interventions

  • fezolinetantDrug

    Oral Tablet

  • placeboDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
  2. Change From Baseline in The Mean Frequency of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12
  3. Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 4Time frame: Baseline and week 4
  4. Change From Baseline in The Mean Severity of Moderate to Severe VMS at Week 12Time frame: Baseline and week 12

Locations

96 sites in 7 countries. Site status is shown where the registry gives one.

  • SEC Clinical Research

    Andalusia, Alabama

  • Central Research Associates

    Birmingham, Alabama

  • Achieve Clinical Research, LLC

    Ensley, Alabama

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Eclipse Clinical Research

    Tucson, Arizona

  • Advanced Clinical Research - Rancho Paseo

    Banning, California

  • Hope Clinical Research, LLC

    Canoga Park, California

  • Alliance Research Inc

    Canoga Park, California

  • Marvel Clinical Research

    Huntington Beach, California

  • Grossmont Center for Clinical Research

    La Mesa, California

  • National Research Institute - Panorama

    Los Angeles, California

  • Northern California Research

    Sacramento, California

  • Precision Research Institute, Inc

    San Diego, California

  • Coastal Connecticut Research, LLC

    New London, Connecticut

  • Emerson Clinical Research Institute

    Washington D.C., District of Columbia

  • Precision Clinical Research

    Coral Springs, Florida

  • American Research Institute, Inc.

    Cutler Bay, Florida

  • Avail Clinical Research, LLC

    DeLand, Florida

  • Universal Axon Clinical Research

    Doral, Florida

  • Fleming Island Center for Clinical Research

    Fleming Island, Florida

  • Clinical Physiology Associates

    Fort Myers, Florida

  • Vital Pharma Research Inc.

    Hialeah, Florida

  • Health Awareness

    Jupiter, Florida

  • GYN Research Center

    Kissimmee, Florida

  • Multi-Specialty Research Associates, Inc.

    Lake City, Florida

  • Altus Research

    Lake Worth, Florida

  • Medical Research Center of Miami II

    Miami, Florida

  • Spotlight research center

    Miami, Florida

  • New Age Medical Research Corporation

    Miami, Florida

  • Suncoast Clinical Research, Inc.

    New Port Richey, Florida

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida

  • Clinical Neuroscience Solutions, Inc

    Orlando, Florida

  • Cornerstone Research Institute

    Orlando, Florida

  • St. Johns Center for Clinical Research

    Ponte Vedra, Florida

  • Health Awareness

    Port Saint Lucie, Florida

  • International Clinical Research

    Sanford, Florida

  • Premier Medical Associates

    The Villages, Florida

  • Better Health Greater Life

    Atlanta, Georgia

  • Gwinnett Research Institute

    Buford, Georgia

  • IACT Health

    Columbus, Georgia

Showing 40 of 96 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.